<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR8">
 <label>8.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Shannon</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Le</surname>
    <given-names>NT</given-names>
   </name>
   <name>
    <surname>Selisko</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Eydoux</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Alvarez</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Guillemot</surname>
    <given-names>JC</given-names>
   </name>
   <name>
    <surname>Decroly</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Peersen</surname>
    <given-names>O</given-names>
   </name>
   <name>
    <surname>Ferron</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Canard</surname>
    <given-names>B</given-names>
   </name>
  </person-group>
  <article-title>Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites</article-title>
  <source>Antiviral Res</source>
  <year>2020</year>
  <volume>178</volume>
  <fpage>104793</fpage>
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104793</pub-id>
  <?supplied-pmid 32283108?>
  <pub-id pub-id-type="pmid">32283108</pub-id>
 </element-citation>
</ref>
